ENHERTU® Approved in the U.S. as First Tumor Agnostic H

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Apr 5, 2024--

Related Keywords

Texas , United States , Japan , Australia , Brazil , Singapore , Tokyo , American , America , Daiichi Sankyo , Jennifer Brennan , Dave Fredrickson , Ken Keller , American Society Of Clinical Oncology , European Society For Medical Oncology , Astrazeneca , Merck Co Inc , University Of Texas Md Anderson Cancer Center , Daiichi Sankyo Co Ltd , Nasdaq , Clinical Development Program , Drug Administration , Daiichi Sankyo Inc , Virtual Congress , National Comprehensive Cancer Network , Real Time Oncology Review , Priority Review , Breakthrough Therapy , Project Orbis , Funda Meric Bernstam , Investigational Cancer Therapeutics , Global Head , Oncology Business , Executive Vice President , Oncology Business Unit , Prescribing Information , Practice Guidelines , Medical Oncology , New England Journal , Lancet Oncology , Clinical Oncology , Lung Disease , Low Metastatic Breast Cancer , Solid Tumors , Positive Locally Advanced , Metastatic Gastric Cancer , Absolute Neutrophil Count , Positive Metastatic Breast , Low Metastatic Breast , Mutant Unresectable , Metastatic Solid , Reproductive Potential , Hepatic Impairment , Accessed April , Media Contacts , Business Wire ,